In conclusion, we observed that pan-HDACi treatment represses TET2 expression mainly through HDAC4 inhibition, leading to impaired DNA demethylation capacity in high-risk MDS/AML. The gene discussed is HDAC4; the disease is acute myeloid leukemia.